TY - JOUR T1 - Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease JF - BMJ Case Reports JO - BMJ Case Reports DO - 10.1136/bcr-2018-225680 VL - 12 IS - 2 SP - bcr-2018-225680 AU - Talal Alzahrani AU - Abdulelah Nuqali AU - Nejat Naser AU - Amar R Jariwala Y1 - 2019/02/01 UR - http://casereports.bmj.com/content/12/2/bcr-2018-225680.abstract N2 - We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies. ER -